214 related articles for article (PubMed ID: 23018647)
41. A novel mode of FoxM1 regulation: positive auto-regulatory loop.
Halasi M; Gartel AL
Cell Cycle; 2009 Jun; 8(12):1966-7. PubMed ID: 19411834
[TBL] [Abstract][Full Text] [Related]
42. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
[TBL] [Abstract][Full Text] [Related]
43. A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death.
Kim H; Lee JY; Park KJ; Kim WH; Roh GS
BMC Neurosci; 2016 Jun; 17(1):33. PubMed ID: 27287829
[TBL] [Abstract][Full Text] [Related]
44. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression.
Zhang M; Liu Y; Gao Y; Li S
Eur J Pharmacol; 2015 Oct; 765():346-54. PubMed ID: 26342429
[TBL] [Abstract][Full Text] [Related]
45. Triphenylphosphonium derivatives disrupt metabolism and inhibit melanoma growth in vivo when delivered via a thermosensitive hydrogel.
Kloepping KC; Kraus AS; Hedlund DK; Gnade CM; Wagner BA; McCormick ML; Fath MA; Seol D; Lim TH; Buettner GR; Goswami PC; Pigge FC; Spitz DR; Schultz MK
PLoS One; 2020; 15(12):e0244540. PubMed ID: 33378390
[TBL] [Abstract][Full Text] [Related]
46. Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs).
Ozsvari B; Sotgia F; Lisanti MP
Aging (Albany NY); 2018 Feb; 10(2):229-240. PubMed ID: 29466249
[TBL] [Abstract][Full Text] [Related]
47. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
48. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.
Uddin S; Ahmed M; Hussain A; Abubaker J; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Jehan Z; Bavi P; Siraj AK; Al-Kuraya KS
Am J Pathol; 2011 Feb; 178(2):537-47. PubMed ID: 21281787
[TBL] [Abstract][Full Text] [Related]
49. Targeting FOXM1 in cancer.
Halasi M; Gartel AL
Biochem Pharmacol; 2013 Mar; 85(5):644-652. PubMed ID: 23103567
[TBL] [Abstract][Full Text] [Related]
50. Mdivi-1, mitochondrial fission inhibitor, impairs developmental competence and mitochondrial function of embryos and cells in pigs.
Yeon JY; Min SH; Park HJ; Kim JW; Lee YH; Park SY; Jeong PS; Park H; Lee DS; Kim SU; Chang KT; Koo DB
J Reprod Dev; 2015; 61(2):81-9. PubMed ID: 25501014
[TBL] [Abstract][Full Text] [Related]
51. Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase.
Myers CR
Free Radic Biol Med; 2016 Feb; 91():81-92. PubMed ID: 26686468
[TBL] [Abstract][Full Text] [Related]
52. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
Chen Y; Ruben EA; Rajadas J; Teng NNH
Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
[TBL] [Abstract][Full Text] [Related]
53. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
[TBL] [Abstract][Full Text] [Related]
54. FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation.
Black M; Arumugam P; Shukla S; Pradhan A; Ustiyan V; Milewski D; Kalinichenko VV; Kalin TV
Mol Biol Cell; 2020 Jun; 31(13):1411-1424. PubMed ID: 32348194
[TBL] [Abstract][Full Text] [Related]
55. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
57. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
58. Mitochondrial division inhibitor 1 (mdivi-1) increases oxidative capacity and contractile stress generated by engineered skeletal muscle.
Rexius-Hall ML; Khalil NN; Andres AM; McCain ML
FASEB J; 2020 Sep; 34(9):11562-11576. PubMed ID: 32652761
[TBL] [Abstract][Full Text] [Related]
59. Peroxiredoxin 5 (Prx5) decreases LPS-induced microglial activation through regulation of Ca
Park J; Choi H; Kim B; Chae U; Lee DG; Lee SR; Lee S; Lee HS; Lee DS
Free Radic Biol Med; 2016 Oct; 99():392-404. PubMed ID: 27585948
[TBL] [Abstract][Full Text] [Related]
60. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
